

Andrés José María Ferreri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2206165/publications.pdf>

Version: 2024-02-01

258
papers

18,595
citations

10986

71
h-index

15732

125
g-index

262
all docs

262
docs citations

262
times ranked

12769
citing authors

#	ARTICLE	IF	CITATIONS
1	Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5034-5043.	1.6	729
2	Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience. <i>Journal of Clinical Oncology</i> , 2003, 21, 266-272.	1.6	688
3	MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4021-4031.	1.4	596
4	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet</i> , 2009, 374, 1512-1520.	13.7	588
5	Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the cutaneous variant. <i>British Journal of Haematology</i> , 2004, 127, 173-183.	2.5	535
6	Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas. <i>Journal of the National Cancer Institute</i> , 2004, 96, 586-594.	6.3	533
7	Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. <i>Blood</i> , 2003, 101, 2489-2495.	1.4	494
8	Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2007, 25, 3168-3173.	1.6	449
9	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e217-e227.	4.6	442
10	Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2003, 102, 2741-2745.	1.4	391
11	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology</i> , 2015, 16, e322-e332.	10.7	340
12	Diffuse large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 146-171.	4.4	323
13	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2012, 120, 3986-3996.	1.4	301
14	Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti-Helicobacter Pylori Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 1979-1983.	1.6	265
15	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	4.6	258
16	Regression of Ocular Adnexal Lymphoma After Chlamydia Psittaci Eradicating Antibiotic Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 5067-5073.	1.6	211
17	CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2013, 121, 2715-2724.	1.4	206
18	Bacteria-Eradicating Therapy With Doxycycline in Ocular Adnexal MALT Lymphoma: A Multicenter Prospective Trial. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1375-1382.	6.3	201

#	ARTICLE	IF	CITATIONS
19	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2766-2772.	1.6	190
20	Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 2233-2239.	1.6	188
21	Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 152-171.	329.8	177
22	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011, 117, 1595-1604.	1.4	173
23	Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 454-462.	1.6	169
24	<i>Chlamydia Psittaci</i> Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2988-2994.	1.6	167
25	Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. <i>Haematologica</i> , 2007, 92, 486-492.	3.5	164
26	How I treat primary CNS lymphoma. <i>Blood</i> , 2011, 118, 510-522.	1.4	162
27	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 1905-1912.	1.6	143
28	Lymphoblastic lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 330-343.	4.4	141
29	Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. <i>Haematologica</i> , 2002, 87, 1258-64.	3.5	141
30	Intravascular lymphoma: a neoplasm of "homeless" lymphocytes?. <i>Hematological Oncology</i> , 2006, 24, 105-112.	1.7	132
31	Chronic lymphocytic leukaemia. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 104, 169-182.	4.4	126
32	Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. <i>European Journal of Cancer</i> , 2004, 40, 1682-1688.	2.8	118
33	Prevalence and Clinical Implications of Epstein-Barr Virus Infection in <i>De Novo</i> Diffuse Large B-Cell Lymphoma in Western Countries. <i>Clinical Cancer Research</i> , 2014, 20, 2338-2349.	7.0	117
34	Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. <i>Leukemia and Lymphoma</i> , 2008, 49, 43-51.	1.3	116
35	Modulated Chemotherapy According to Modified Comprehensive Geriatric Assessment in 100 Consecutive Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2012, 17, 838-846.	3.7	114
36	Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. <i>Neuro-Oncology</i> , 2019, 21, 296-305.	1.2	114

#	ARTICLE	IF	CITATIONS
37	How we diagnose and treat vitreoretinal lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 680-692.	2.5	113
38	Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. <i>Journal of Clinical Oncology</i> , 2012, 30, 3848-3853.	1.6	107
39	Primary testicular lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 183-189.	4.4	106
40	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. <i>Cancer Immunology Research</i> , 2019, 7, 644-657.	3.4	106
41	Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 483-488.	0.8	103
42	Primary and secondary bone lymphomas. <i>Cancer Treatment Reviews</i> , 2015, 41, 235-246.	7.7	101
43	Ocular Adnexal Lymphoma: Diffusion-weighted MR Imaging for Differential Diagnosis and Therapeutic Monitoring. <i>Radiology</i> , 2010, 256, 565-574.	7.3	100
44	High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 3903-3910.	1.6	99
45	Anaplastic large cell lymphoma, ALK-positive. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 293-302.	4.4	98
46	The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in Western patients with intravascular large B-cell lymphoma. <i>British Journal of Haematology</i> , 2008, 143, 253-257.	2.5	96
47	Peripheral T-cell lymphoma Not otherwise specified. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 321-329.	4.4	95
48	Hodgkin lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 216-237.	4.4	93
49	Prognostic impact of concurrent <i>MYC</i> and <i>BCL6</i> rearrangements and expression in <i>de novo</i> diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 2401-2416.	1.8	93
50	Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. <i>British Journal of Haematology</i> , 2015, 168, 654-662.	2.5	90
51	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	2.8	90
52	Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. <i>British Journal of Haematology</i> , 2002, 118, 817-820.	2.5	87
53	Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. <i>International Journal of Cancer</i> , 2010, 127, 2300-2312.	5.1	86
54	Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. <i>Blood</i> , 2012, 120, 3222-3228.	1.4	85

#	ARTICLE	IF	CITATIONS
55	The role of autologous stem cell transplantation in primary central nervous system lymphoma. <i>Blood</i> , 2016, 127, 1642-1649.	1.4	85
56	Chronic lymphocytic leukemia. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 64, 234-246.	4.4	84
57	MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. <i>Neurology</i> , 2006, 66, 1435-1438.	1.1	83
58	Chlamydia Infection and Lymphomas: Association Beyond Ocular Adnexal Lymphomas Highlighted by Multiple Detection Methods. <i>Clinical Cancer Research</i> , 2008, 14, 5794-5800.	7.0	83
59	Enteropathy-associated T-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 84-90.	4.4	83
60	Diffuse Large-Cell Lymphoma of the Testis. <i>Journal of Clinical Oncology</i> , 1999, 17, 2854-2854.	1.6	82
61	Combined Treatment with High-Dose Methotrexate, Vincristine and Procarbazine, without Intrathecal Chemotherapy, Followed by Consolidation Radiotherapy for Primary Central Nervous System Lymphoma in Immunocompetent Patients. <i>Oncology</i> , 2001, 60, 134-140.	1.9	82
62	Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 419-425.	0.8	82
63	Primary diffuse large B-cell lymphoma of the stomach. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 63, 65-71.	4.4	82
64	Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. <i>Seminars in Cancer Biology</i> , 2014, 24, 33-42.	9.6	80
65	Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion. , 1996, 77, 827-833.		79
66	Gela histological scoring system for post-treatment biopsies of patients with gastric <scp>MALT</scp> lymphoma is feasible and reliable in routine practice. <i>British Journal of Haematology</i> , 2013, 160, 47-52.	2.5	79
67	Primary central nervous system lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 97-110.	4.4	79
68	CNS Hodgkin lymphoma. <i>Blood</i> , 2008, 112, 1658-1661.	1.4	76
69	Marginal zone lymphomas and infectious agents. <i>Seminars in Cancer Biology</i> , 2013, 23, 431-440.	9.6	76
70	Mycosis fungoides. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 65, 172-182.	4.4	75
71	Lymphoplasmacytic lymphomaâ€“Waldenstrom's macroglobulinemia. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 172-185.	4.4	75
72	Flows and flaws in primary central nervous system lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 1-2.	27.6	75

#	ARTICLE	IF	CITATIONS
73	Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. <i>British Journal of Haematology</i> , 2004, 126, 657-664.	2.5	73
74	Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. <i>British Journal of Haematology</i> , 2010, 150, 226-229.	2.5	72
75	Clinical and biological significance of <i>de novo</i> CD5+ diffuse large B-cell lymphoma in Western countries. <i>Oncotarget</i> , 2015, 6, 5615-5633.	1.8	72
76	Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 651-658.	0.8	71
77	Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. <i>Hematological Oncology</i> , 2009, 27, 61-70.	1.7	70
78	Intralesional Rituximab. <i>Ophthalmology</i> , 2011, 118, 24-28.	5.2	70
79	Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study). <i>Oncologist</i> , 2014, 19, 291-298.	3.7	70
80	Gamma-delta T-cell lymphomas. <i>European Journal of Haematology</i> , 2015, 94, 206-218.	2.2	69
81	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). <i>Neuro-Oncology</i> , 2021, 23, 1056-1071.	1.2	68
82	Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. <i>Haematologica</i> , 2005, 90, 1578-9.	3.5	67
83	<i>Chlamydia psittaci</i> is viable and infectious in the conjunctiva and peripheral blood of patients with ocular adnexal lymphoma: Results of a single-centre prospective case-control study. <i>International Journal of Cancer</i> , 2008, 123, 1089-1093.	5.1	66
84	Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. <i>Haematologica</i> , 2008, 93, 1364-1371.	3.5	66
85	Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-E regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. <i>Hematological Oncology</i> , 2013, 31, 143-150.	1.7	66
86	Prognostic Significance of the Histopathologic Recognition of Low-and High-Grade Components in Stage I-II B-Cell Gastric Lymphomas. <i>American Journal of Surgical Pathology</i> , 2001, 25, 95-102.	3.7	64
87	Angioimmunoblastic T-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, 264-271.	4.4	64
88	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018, 29, 544-562.	1.2	64
89	Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. <i>Neoplasia</i> , 2018, 20, 574-593.	5.3	64
90	Can Rituximab Change the Usually Dismal Prognosis of Patients With Intravascular Large B-Cell Lymphoma?. <i>Journal of Clinical Oncology</i> , 2008, 26, 5134-5136.	1.6	61

#	ARTICLE	IF	CITATIONS
91	Prevalence of <i>Borrelia burgdorferi</i> Infection in a Series of 98 Primary Cutaneous Lymphomas. <i>Oncologist</i> , 2011, 16, 1582-1588.	3.7	61
92	Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 5597-5614.	1.8	61
93	Primary central nervous system lymphoma – Biological aspects and controversies in management. <i>European Journal of Cancer</i> , 2007, 43, 1141-1152.	2.8	60
94	Primary mediastinal large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, 256-263.	4.4	60
95	Chlorambucil versus observation after anti- <i>Helicobacter</i> therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. <i>British Journal of Haematology</i> , 2009, 144, 367-375.	2.5	60
96	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2014, 20, 5113-5123.	7.0	60
97	Marginal-zone lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 63, 245-256.	4.4	59
98	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 3083-3100.	1.4	59
99	<i>Helicobacter pylori</i> eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. <i>Blood</i> , 2012, 120, 3858-3860.	1.4	58
100	Chlamydial infection: the link with ocular adnexal lymphomas. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 658-669.	27.6	57
101	Consolidation Radiotherapy to Bulky or Semibulky Lesions in the Management of Stage III-IV Diffuse Large B Cell Lymphomas. <i>Oncology</i> , 2000, 58, 219-226.	1.9	56
102	Consolidation Radiotherapy in Primary Central Nervous System Lymphomas: Impact on Outcome of Different Fields and Doses in Patients in Complete Remission After Upfront Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 169-175.	0.8	56
103	Target delineation in post-operative radiotherapy of brain gliomas: Interobserver variability and impact of image registration of MR(pre-operative) images on treatment planning CT scans. <i>Radiotherapy and Oncology</i> , 2005, 75, 217-223.	0.6	54
104	Rituximab in primary central nervous system lymphoma – A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 548-557.	1.7	54
105	MATRIx – RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e110-e121.	4.6	54
106	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma – a randomized phase III trial (MATRIx). <i>BMC Cancer</i> , 2016, 16, 282.	2.6	53
107	mTOR inhibitors and their potential role in haematological malignancies. <i>British Journal of Haematology</i> , 2017, 177, 684-702.	2.5	53
108	Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1609-1618.	3.7	52

#	ARTICLE	IF	CITATIONS
109	Primary CNS lymphoma. Best Practice and Research in Clinical Haematology, 2012, 25, 119-130.	1.7	52
110	Hepatosplenic gamma-delta T-cell lymphoma. Critical Reviews in Oncology/Hematology, 2012, 83, 283-292.	4.4	51
111	Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology American Society of Hematology Education Program, 2017, 2017, 565-577.	2.5	51
112	MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA. Retina, 2019, 39, 679-684.	1.7	50
113	Association between Helicobacter pylori infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications. Hematological Oncology, 2006, 24, 33-37.	1.7	48
114	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Modern Pathology, 2015, 28, 1555-1573.	5.5	48
115	Re: Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas. Journal of the National Cancer Institute, 2006, 98, 365-366.	6.3	47
116	Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP. British Journal of Haematology, 2010, 151, 221-231.	2.5	47
117	Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. British Journal of Haematology, 2011, 155, 274-277.	2.5	47
118	Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 2022, 36, 1870-1878.	7.2	47
119	MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 2630-2640.	1.4	46
120	High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leukemia and Lymphoma, 2008, 49, 2042-2047.	1.3	45
121	Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. Blood, 2019, 134, 353-362.	1.4	45
122	Follicular lymphomas. Critical Reviews in Oncology/Hematology, 2008, 66, 248-261.	4.4	44
123	Ocular adnexal marginal zone lymphoma: Clinical presentation, pathogenesis, diagnosis, prognosis, and treatment. Best Practice and Research in Clinical Haematology, 2017, 30, 118-130.	1.7	44
124	R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor- α in primary CNS lymphoma. Blood, 2019, 134, 252-262.	1.4	43
125	Genomic profiles of MALT lymphomas: variability across anatomical sites. Haematologica, 2011, 96, 1064-1066.	3.5	42
126	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood, 2022, 139, 2499-2511.	1.4	42

#	ARTICLE	IF	CITATIONS
127	Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 121, 4529-4540.	1.4	41
128	<i>MYD88</i> L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study. <i>British Journal of Haematology</i> , 2021, 193, 497-505.	2.5	41
129	Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice. <i>British Journal of Haematology</i> , 2020, 189, 879-887.	2.5	41
130	Infectious Agents in Mucosa-Associated Lymphoid Tissue-Type Lymphomas: Pathogenic Role and Therapeutic Perspectives. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 289-300.	1.4	39
131	Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the international extranodal lymphoma study group. <i>British Journal of Haematology</i> , 2014, 166, 69-76.	2.5	39
132	AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1700-1716.	3.8	39
133	MATILDE chemotherapy regimen for primary CNS lymphoma. <i>Neurology</i> , 2014, 82, 1370-1373.	1.1	38
134	Variable association between <i>Chlamydia psittaci</i> infection and ocular adnexal lymphomas: methodological biases or true geographical variations?. <i>Anti-Cancer Drugs</i> , 2008, 19, 761-765.	1.4	37
135	Whole-brain radiotherapy in primary CNS lymphoma. <i>Lancet Oncology</i> , The, 2011, 12, 118-119.	10.7	37
136	Risk of CNS dissemination in extranodal lymphomas. <i>Lancet Oncology</i> , The, 2014, 15, e159-e169.	10.7	37
137	A Reappraisal of the Diagnostic and Therapeutic Management of Uncommon Histologies of Primary Ocular Adnexal Lymphoma. <i>Oncologist</i> , 2013, 18, 876-884.	3.7	36
138	The role of whole brain radiation in primary CNS lymphoma. <i>Blood</i> , 2016, 128, 32-36.	1.4	35
139	Evolving Treatments for Primary Central Nervous System Lymphoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 454-466.	3.8	35
140	Prognostic impact of c-Rel nuclear expression and <i>REL</i> amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2015, 6, 23157-23180.	1.8	35
141	Primary central nervous system lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 63, 257-268.	4.4	34
142	Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. <i>Oncotarget</i> , 2015, 6, 13933-13945.	1.8	33
143	Primary central nervous system lymphomas: Salvage treatment after failure to high-dose methotrexate. <i>Cancer Letters</i> , 2007, 258, 165-170.	7.2	32
144	The role of <i>Helicobacter pylori</i> eradication in the treatment of diffuse large B-cell and marginal zone lymphomas of the stomach. <i>Current Opinion in Oncology</i> , 2013, 25, 470-479.	2.4	32

#	ARTICLE	IF	CITATIONS
145	Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature. <i>Oncologist</i> , 2015, 20, 915-925.	3.7	31
146	Primary central nervous system lymphoma in immunocompetent patients. <i>Cancer Treatment Reviews</i> , 1995, 21, 415-446.	7.7	30
147	Therapeutic Management of Stage I-II High-Grade Primary Gastric Lymphomas. <i>Oncology</i> , 1999, 56, 274-282.	1.9	30
148	A Woman and Her Canary: A Tale of Chlamydiae and Lymphomas. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1418-1419.	6.3	30
149	Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination. <i>Oncologist</i> , 2011, 16, 336-341.	3.7	30
150	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , 2011, 29, 38-41.	1.7	29
151	RelA NF- κ B subunit activation as a therapeutic target in diffuse large B-cell lymphoma. <i>Aging</i> , 2016, 8, 3321-3340.	3.1	29
152	Intravascular large B-cell lymphoma. , 2008, , 147-154.		29
153	Prognostic value of bcl-6, CD10 and CD38 immunoreactivity in stage I-II gastric lymphomas: Identification of a subset of CD10+ large B-cell lymphomas with a favorable outcome. <i>International Journal of Cancer</i> , 2003, 106, 288-291.	5.1	28
154	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). <i>Annals of Hematology</i> , 2011, 90, 401-408.	1.8	28
155	Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 240-247.	2.4	28
156	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e137-e146.	4.6	28
157	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	5.2	28
158	Prognostic Factors in Primary Central Nervous System Lymphomas. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 629-649.	2.2	27
159	Bacteria associated with marginal zone lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 32-40.	1.7	27
160	XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53. <i>Journal of Hematology and Oncology</i> , 2020, 13, 148.	17.0	27
161	Therapeutic Management with Adriamycin-Containing Chemotherapy and Radiotherapy of Monostotic and Polyostotic Primary Non-Hodgkin's Lymphoma of Bone in Adults. <i>Cancer Investigation</i> , 1998, 16, 554-561.	1.3	25
162	Gastric lymphoma: The histology report. <i>Digestive and Liver Disease</i> , 2011, 43, S310-S318.	0.9	25

#	ARTICLE	IF	CITATIONS
163	Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. <i>Blood Advances</i> , 2020, 4, 3648-3658.	5.2	24
164	Clarithromycin as a repurposing drug against MALT lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 913-915.	2.5	23
165	Primary brain lymphomas in patients with a prior or concomitant malignancy. <i>Journal of Neuro-Oncology</i> , 1997, 32, 135-142.	2.9	22
166	Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies. , 2019, 7, 272.		22
167	A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL. <i>Blood Advances</i> , 2020, 4, 3391-3404.	5.2	22
168	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. <i>Blood Advances</i> , 2021, 5, 640-648.	5.2	22
169	Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2022, 28, 972-983.	7.0	22
170	Immunoreactivity for p27KIP1 and cyclin E is an independent predictor of survival in primary gastric non-Hodgkin's lymphoma. <i>International Journal of Cancer</i> , 2001, 94, 599-604.	5.1	21
171	Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. <i>Modern Pathology</i> , 2015, 28, 1297-1314.	5.5	21
172	Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. <i>Modern Pathology</i> , 2004, 17, 1513-1520.	5.5	20
173	Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18 FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. <i>British Journal of Haematology</i> , 2017, 178, 588-591.	2.5	20
174	Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. <i>Molecular Cancer Research</i> , 2021, 19, 249-260.	3.4	20
175	The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. <i>British Journal of Haematology</i> , 2002, 118, 218-228.	2.5	19
176	International Collaborative Group Against Primary CNS Lymphomas. <i>Journal of Clinical Oncology</i> , 2003, 21, 1649-1650.	1.6	19
177	Current uses of radiation therapy in patients with primary CNS lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1327-1337.	2.4	19
178	Breaching the Blood-Brain Tumor Barrier for Tumor Therapy. <i>Cancers</i> , 2021, 13, 2391.	3.7	19
179	p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. <i>Aging</i> , 2016, 8, 345-365.	3.1	19
180	Is Withdrawal of Consolidation Radiotherapy an Evidence-Based Strategy in Primary Central Nervous System Lymphomas?. <i>Journal of Clinical Oncology</i> , 2004, 22, 1165-1167.	1.6	18

#	ARTICLE	IF	CITATIONS
181	Central nervous system marginal zone B-cell lymphoma associated with <i>Chlamydomonas psittaci</i> infection. <i>Human Pathology</i> , 2011, 42, 738-742.	2.0	18
182	Long-Term Remission of HIV-Associated Primary CNS Lymphoma Achieved With Highly Active Antiretroviral Therapy Alone. <i>Journal of Clinical Oncology</i> , 2012, 30, e119-e121.	1.6	18
183	Evaluation of NF- κ B subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions. <i>Modern Pathology</i> , 2015, 28, 1202-1213.	5.5	17
184	Role of Dose Intensity in Conservative Treatment of Anal Canal Carcinoma. <i>Oncology</i> , 1998, 55, 525-532.	1.9	16
185	Present and future treatment options for primary CNS lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2569-2579.	1.8	16
186	Treatment approaches for primary CNS lymphomas. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1263-1276.	1.8	15
187	Genetic and epigenetic changes linked to <i>Chlamydomonas psittaci</i> -associated ocular adnexal lymphomas. <i>Hematological Oncology</i> , 2010, 28, 1-2.	1.7	15
188	Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. <i>British Journal of Haematology</i> , 2012, 159, 252-255.	2.5	15
189	Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 62-68.	1.3	14
190	A Retrospective Analysis of Postradiation Chemotherapy in 133 Patients with Glioblastoma Multiforme. <i>Cancer Investigation</i> , 2000, 18, 510-515.	1.3	12
191	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , 2011, 153, 499-503.	2.5	12
192	Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum. <i>Blood Advances</i> , 2020, 4, 1013-1019.	5.2	11
193	Ten Years of International Primary CNS Lymphoma Collaborative Group Studies. <i>Journal of Clinical Oncology</i> , 2013, 31, 3444-3445.	1.6	10
194	De-escalating therapy in gastric aggressive lymphoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 8993-7.	3.3	10
195	Establishing a prognostic score for primary CNS lymphomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 303-304.	0.8	9
196	A phase I/II study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. <i>Blood Advances</i> , 2021, 5, 4073-4082.	5.2	9
197	Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphomas in the absence of the t(6;14)(p21.1;q32.3) chromosomal translocation. <i>Journal of Pathology</i> , 2003, 200, 596-601.	4.5	8
198	Primary CNS Lymphomas Prognosis. <i>Journal of Clinical Oncology</i> , 2007, 25, 4322-4324.	1.6	8

#	ARTICLE	IF	CITATIONS
199	The impact of histopathologic diagnosis on the proper management of testis neoplasms. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 619-622.	4.3	8
200	Risk stratification and management algorithms for patients with diffuse large B-cell lymphoma and CNS involvement. <i>Annals of Lymphoma</i> , 0, 3, 7-7.	4.5	8
201	Early serum <sc>TARC</sc> reduction predicts prognosis in advanced“stage <sc>Hodgkin</sc> lymphoma patients treated with a <sc>PET</sc>-adapted strategy. <i>Hematological Oncology</i> , 2020, 38, 501-508.	1.7	8
202	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus“Associated Indolent Non-Hodgkin Lymphomas: The BA“T Study of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2022, 40, 4060-4070.	1.6	8
203	Therapeutic management of ocular adnexal MALT lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1073-1083.	1.8	7
204	Intravascular Large B Cell Lymphoma: Widespread but Not Everywhere. <i>Acta Haematologica</i> , 2014, 131, 16-17.	1.4	7
205	Long“lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B“cell lymphoma who are not eligible for or failed autologous transplantation. <i>Hematological Oncology</i> , 2020, 38, 257-265.	1.7	7
206	A dose“dense short“term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high“risk Burkitt lymphoma or high“grade B“cell lymphoma: safety and efficacy results of the “CARMEN“-phase II trial. <i>British Journal of Haematology</i> , 2021, 192, 119-128.	2.5	7
207	Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10. <i>Blood</i> , 2016, 128, 1099-1099.	1.4	7
208	Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. <i>Blood Cancer Journal</i> , 2022, 12, 25.	6.2	7
209	Activity of Clarithromycin in Mucosa-Associated Lymphoid Tissue-Type Lymphomas. <i>Chest</i> , 2011, 139, 724-725.	0.8	6
210	Gains of <i><sc>CCND</sc>3</i> gene in ocular adnexal <sc>MALT</sc> lymphomas: an integrated analysis. <i>British Journal of Haematology</i> , 2013, 160, 719-722.	2.5	6
211	Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 379-393.	2.8	6
212	NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity. <i>Molecular Pharmaceutics</i> , 2020, 17, 3813-3824.	4.6	6
213	Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. <i>Oncolmmunology</i> , 2021, 10, 1928365.	4.6	6
214	Consolidation Radiotherapy for a Rare Case of Extranodal Mucosa-Associated Lymphoid Tissue Non-Hodgkin's Lymphoma Synchronous with Prostate Adenocarcinoma. <i>Tumori</i> , 2010, 96, 498-502.	1.1	5
215	Production and Characterization of a Monoclonal Antibody Against the Ribosome Inactivating Protein Alpha Sarcin. <i>Hybridoma</i> , 1992, 11, 437-446.	0.6	4
216	Therapeutic management of primary CNS lymphoma in immunocompetent patients. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 382-394.	2.4	4

#	ARTICLE	IF	CITATIONS
217	Primary intracranial meningeal marginal zone B cell lymphoma of malt type (PMML) with osseous infiltration. <i>Annals of Hematology</i> , 2009, 88, 599-601.	1.8	4
218	Who Is Who in Primary Vitreoretinal Lymphoma?. <i>JAMA Oncology</i> , 2015, 1, 977.	7.1	4
219	Targeted therapies make room, anti-CD79b agents are coming. <i>Lancet Oncology</i> , The, 2019, 20, 898-900.	10.7	4
220	Low Sensitivity of Computed Tomography in the Staging of Gastric Lymphomas of Mucosa-Associated Lymphoid Tissue. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 614-616.	1.3	4
221	Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103496.	4.4	4
222	Targeting the Blood-Brain Tumor Barrier with Tumor Necrosis Factor- α . <i>Pharmaceutics</i> , 2022, 14, 1414.	4.5	4
223	A Virtual Tissue Bank for Primary Central Nervous System Lymphomas in Immunocompetent Individuals. <i>Pathobiology</i> , 2007, 74, 264-269.	3.8	3
224	Bugs and marginal zone lymphoma of the ocular adnexae: is the future already here?. <i>Blood</i> , 2009, 114, 3499-3499.	1.4	3
225	Marginal zone B-cell lymphoma of the conjunctiva. <i>Expert Review of Ophthalmology</i> , 2010, 5, 177-188.	0.6	3
226	The t(14;18)(q32;q21) Characterizes a Subset of Patients with Diffuse Large-B Cell Lymphoma of Germinal Center Origin with Poor Outcome: Report From the International DLBCL Rituximab-CHOP Consortium Program Study. <i>Blood</i> , 2011, 118, 949-949.	1.4	3
227	Questions and answers in the management of primary central nervous system and ocular lymphomas. <i>Haematologica</i> , 2003, 88, 1063-8.	3.5	3
228	Irradiation Fields and Doses in Glioblastoma Multiforme: Are Current Standards Adequate?. <i>Tumori</i> , 2001, 87, 85-90.	1.1	2
229	Current therapeutic approaches to primary CNS lymphoma. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 673-683.	2.8	2
230	Unconventional therapies in ocular adnexal lymphomas. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1341-1343.	2.4	2
231	A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type. <i>Blood</i> , 2008, 112, 3062-3062.	1.4	2
232	A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma. <i>Expert Review of Hematology</i> , 2021, , 1-11.	2.2	2
233	No association between polyomaviruses and primary central nervous system lymphomas of HIV-seronegative and HIV-positive patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1819-20.	2.5	2
234	Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma. <i>Blood Advances</i> , 2022, 6, 5811-5820.	5.2	2

#	ARTICLE	IF	CITATIONS
235	Central nervous system lymphoma. , 2001, , 200-214.		1
236	Bendamustine plus rituximab in MALT lymphoma. Lancet Haematology,the, 2014, 1, e88-e89.	4.6	1
237	Primary central nervous system lymphoma: three linked questions in the situation puzzle of radiotherapy. Leukemia and Lymphoma, 2015, 56, 1185-1187.	1.3	1
238	Reply to A. Korfel et al. Journal of Clinical Oncology, 2016, 34, 1830-1831.	1.6	1
239	Intraocular Lymphoma. , 2012, , 199-218.		1
240	Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma. Expert Opinion on Therapeutic Targets, 2021, 25, 749-760.	3.4	1
241	STAT3 Expression and Clinical Implications In De Novo Diffuse Large B-Cell Lymphoma: A Report From The International DLBCL Rituximab-CHOP Consortium Program. Blood, 2013, 122, 365-365.	1.4	1
242	Cell of Origin Classification of DLBCL Using Targeted NGS Expression Profiling and Deep Learning. Blood, 2019, 134, 2891-2891.	1.4	1
243	Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study. Advances in Hematology, 2022, 2022, 1-10.	1.0	1
244	Appraisal of recent knowledge in primary central nervous system lymphoma. Memo - Magazine of European Medical Oncology, 2012, 5, 285-288.	0.5	0
245	Ocular Adnexal Lymphoma of MALT-Type and Its Association with Chlamydothila psittaci Infection. , 2012, , 139-163.		0
246	Central nervous system lymphomas. , 0, , 208-225.		0
247	Seeking solutions to old problems in elderly patients with lymphoma. Lancet Haematology,the, 2018, 5, e235-e236.	4.6	0
248	mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 85-105.	0.1	0
249	Prevention of CNS relapse in diffuse large B-cell lymphoma: common sense prevails where science fails. British Journal of Haematology, 2020, 190, 645-647.	2.5	0
250	Patience and commitment needed to fight very rare tumours. Lancet Oncology, The, 2020, 21, 483-484.	10.7	0
251	Immunoglobulin Gene Repertoire in Ocular Adnexa Lymphomas (OAL): Hints on the Nature of the Antigenic Stimulation. Blood, 2008, 112, 623-623.	1.4	0
252	The Impact of Therapeutic Management and Prognostic Factors on the Outcome of Primary Cutaneous B-Cell Lymphomas (PCBCL) (IELSG 11 Study). Blood, 2008, 112, 3608-3608.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. <i>Blood</i> , 2008, 112, 478-478.	1.4	0
254	Primary Central Nervous System Lymphomas: Salvage Treatment. , 2011, , 337-351.		0
255	Interim Analysis Of An Ongoing PHASE II Trial Assessing Safety and Efficacy Of Lenalidomide Maintenance In Patients With Chemosensitive Relapse Of Diffuse Large B-CELL Lymphoma (DLBCL). <i>Blood</i> , 2013, 122, 3055-3055.	1.4	0
256	CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL). <i>Frontiers in Oncology</i> , 2021, 11, 730194.	2.8	0
257	Using immunogenetics to inform immunotherapy of lymphoid malignancies. <i>Lancet Haematology</i> , the, 2022, 9, e88-e89.	4.6	0
258	Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial. <i>Blood Advances</i> , 0, , .	5.2	0